{"id":1520,"date":"2020-10-21T08:21:00","date_gmt":"2020-10-21T08:21:00","guid":{"rendered":"https:\/\/www.everpharma.com\/?p=1520"},"modified":"2024-03-13T12:44:50","modified_gmt":"2024-03-13T12:44:50","slug":"ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung","status":"publish","type":"post","link":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/","title":{"rendered":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung"},"content":{"rendered":"\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p>EVER&nbsp;Pharma freut sich, die EU-weite Zulassung von Cabazitaxel anzuk\u00fcndigen, f\u00fcr die Behandlung von M\u00e4nnern mit metastasiertem Prostatakrebs<sup>1<\/sup>.<\/p>\n\n\n\n<p>Das&nbsp;EVER-Produkt verwendet eine neuartige Formulierung, die es erm\u00f6glicht, eine endg\u00fcltige Patientendosis vorzubereiten ohne Vorverd\u00fcnnungsschritte. Dies ist eine bequemere Formulierung, die den sicheren Umgang mit diesem Zytostatikum erm\u00f6glicht, sowie Zeit- und Kosteneinsparungen mit sich bringt im Vergleich zu dem derzeit verf\u00fcgbaren Zwei-Vial System. Das&nbsp;EVER-Produkt f\u00fcgt au\u00dferdem zwei neue Pr\u00e4sentationen hinzu, die den allgemeinen Bereich patientenspezifischer Dosen abdecken, und reduziert dadurch kostspielige Verschwendung, indem die Menge an Produktresten nach Extraktion der Patientendosis reduziert wird.&nbsp;<\/p>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"355\" src=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png\" alt=\"\" class=\"wp-image-2405\" srcset=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png 1024w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-300x104.png 300w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-768x266.png 768w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1536x532.png 1536w, https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1.png 1916w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p><\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-9d6595d7 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\">\n<p>Die Verwendung von Cabazitaxel nimmt stark zu, der europ\u00e4ische Markt wird derzeit auf einen Wert von mehr als \u20ac210 Mio. gesch\u00e4tzt.<\/p>\n\n\n\n<p>\u201eCabazitaxel ist eine teure, aber \u00e4u\u00dferst wichtige Krebsbehandlung. Wir freuen uns, dieses innovative&nbsp;EVER&nbsp;Produkt anbieten zu k\u00f6nnen, dass die sichere und effiziente Vorbereitung der Infusion bietet und das Potenzial hat, den Zugang des Patienten zu dieser Therapie erheblich zu verbessern\u201c sagte Georges Kahwati, General Manager von Ever Pharma.<\/p>\n\n\n\n<p>Die europ\u00e4ische Zulassung von&nbsp;EVER&nbsp;Pharma Cabazitaxel folgt auf die k\u00fcrzliche erfolgte Registrierung in Australien und wird anschlie\u00dfend unter Beachtung lokaler Patentbeschr\u00e4nkungen in wichtigen M\u00e4rkten auf der ganzen Welt eingef\u00fchrt.<\/p>\n<\/div>\n<\/div>\n\n\n\n<div style=\"height:63px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-wpco-accordion accordion\" id=\"accordion-1520-1\">\n<div class=\"wp-block-wpco-accordion-body accordion-item\"><div class=\"accordion-header\" id=\"accordion-1520-1-item-1-heading\"><button class=\"accordion-button has-theme-gray-background-color has-theme-copy-color\" data-bs-toggle=\"collapse\" data-bs-target=\"#accordion-1520-1-item-1-body\">Quellen<\/button><\/div><div class=\"accordion-collapse collapse\" id=\"accordion-1520-1-item-1-body\" aria-labelledby=\"accordion-1520-1-item-1-heading\" data-bs-parent=\"#accordion-1520-1\"><div class=\"accordion-body has-theme-light-gray-background-color has-theme-copy-color\">\n<p><sup>1<\/sup> Cabazitaxel\u00a0EVER\u00a0Pharma in Kombination mit Prednison oder Prednisolon ist zur Behandlung von erwachsenen Patienten mit metastasiertem kastrationsresistentem Prostatakrebs indiziert, die zuvor mit einem Docetaxel-haltigen Regime behandelt wurden.<br><\/p>\n<\/div><\/div><\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>EVER&nbsp;Pharma freut sich, die EU-weite Zulassung von Cabazitaxel anzuk\u00fcndigen, f\u00fcr die Behandlung von M\u00e4nnern mit metastasiertem Prostatakrebs1. Das&nbsp;EVER-Produkt verwendet eine neuartige Formulierung, die es erm\u00f6glicht, eine endg\u00fcltige Patientendosis vorzubereiten ohne Vorverd\u00fcnnungsschritte. Dies ist eine bequemere Formulierung, die den sicheren Umgang mit diesem Zytostatikum erm\u00f6glicht, sowie Zeit- und Kosteneinsparungen mit sich bringt im Vergleich zu dem &hellip; <a href=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/\">Weiterlesen<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-1520","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma\" \/>\n<meta property=\"og:description\" content=\"EVER&nbsp;Pharma freut sich, die EU-weite Zulassung von Cabazitaxel anzuk\u00fcndigen, f\u00fcr die Behandlung von M\u00e4nnern mit metastasiertem Prostatakrebs1. Das&nbsp;EVER-Produkt verwendet eine neuartige Formulierung, die es erm\u00f6glicht, eine endg\u00fcltige Patientendosis vorzubereiten ohne Vorverd\u00fcnnungsschritte. Dies ist eine bequemere Formulierung, die den sicheren Umgang mit diesem Zytostatikum erm\u00f6glicht, sowie Zeit- und Kosteneinsparungen mit sich bringt im Vergleich zu dem &hellip; Weiterlesen\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/\" \/>\n<meta property=\"og:site_name\" content=\"EVER Pharma\" \/>\n<meta property=\"article:published_time\" content=\"2020-10-21T08:21:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-03-13T12:44:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png\" \/>\n<meta name=\"author\" content=\"Magdalena\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Magdalena\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/\"},\"author\":{\"name\":\"Magdalena\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/person\\\/fddfefac0cbd5adf0a20c4e09a52cd65\"},\"headline\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung\",\"datePublished\":\"2020-10-21T08:21:00+00:00\",\"dateModified\":\"2024-03-13T12:44:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/\"},\"wordCount\":260,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Cabazitaxel_Combined-1-1024x355.png\",\"articleSection\":[\"News\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/\",\"name\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Cabazitaxel_Combined-1-1024x355.png\",\"datePublished\":\"2020-10-21T08:21:00+00:00\",\"dateModified\":\"2024-03-13T12:44:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Cabazitaxel_Combined-1-1024x355.png\",\"contentUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Cabazitaxel_Combined-1-1024x355.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/news\\\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#website\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\",\"name\":\"EVER Pharma\",\"description\":\"Dedicated to health.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":[\"Organization\",\"MedicalOrganization\"],\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#organization\",\"name\":\"EVER Pharma\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/ever-pharma-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.everpharma.com\\\/wp-content\\\/uploads\\\/2022\\\/07\\\/ever-pharma-logo.png\",\"width\":240,\"height\":67,\"caption\":\"EVER Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"legalName\":\"EVER Neuro Pharma GmbH\",\"foundingDate\":\"1934-01-01\",\"description\":\"EVER Pharma is a fully integrated specialty pharmaceuticals company specializing in the research, development, and production of sterile injectables and specialty generics for neurology, oncology, intensive care, and hormone therapeutics worldwide.\",\"address\":{\"@type\":\"PostalAddress\",\"streetAddress\":\"Oberburgau 3\",\"addressLocality\":\"Unterach am Attersee\",\"addressRegion\":\"Ober\u00f6sterreich\",\"postalCode\":\"4866\",\"addressCountry\":\"AT\"},\"contactPoint\":{\"@type\":\"ContactPoint\",\"contactType\":\"customer service\",\"telephone\":\"+43 7665 20555 0\",\"email\":\"office@everpharma.com\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ever-pharma\\\/\",\"https:\\\/\\\/www.wikidata.org\\\/wiki\\\/Q30268961\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/#\\\/schema\\\/person\\\/fddfefac0cbd5adf0a20c4e09a52cd65\",\"name\":\"Magdalena\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g\",\"caption\":\"Magdalena\"},\"sameAs\":[\"https:\\\/\\\/everpharma.com\"],\"url\":\"https:\\\/\\\/www.everpharma.com\\\/de\\\/author\\\/mschmitzberger\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma","robots":{"index":"noindex","follow":"follow"},"og_locale":"de_DE","og_type":"article","og_title":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma","og_description":"EVER&nbsp;Pharma freut sich, die EU-weite Zulassung von Cabazitaxel anzuk\u00fcndigen, f\u00fcr die Behandlung von M\u00e4nnern mit metastasiertem Prostatakrebs1. Das&nbsp;EVER-Produkt verwendet eine neuartige Formulierung, die es erm\u00f6glicht, eine endg\u00fcltige Patientendosis vorzubereiten ohne Vorverd\u00fcnnungsschritte. Dies ist eine bequemere Formulierung, die den sicheren Umgang mit diesem Zytostatikum erm\u00f6glicht, sowie Zeit- und Kosteneinsparungen mit sich bringt im Vergleich zu dem &hellip; Weiterlesen","og_url":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/","og_site_name":"EVER Pharma","article_published_time":"2020-10-21T08:21:00+00:00","article_modified_time":"2024-03-13T12:44:50+00:00","og_image":[{"url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png","type":"","width":"","height":""}],"author":"Magdalena","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Magdalena","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#article","isPartOf":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/"},"author":{"name":"Magdalena","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/person\/fddfefac0cbd5adf0a20c4e09a52cd65"},"headline":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung","datePublished":"2020-10-21T08:21:00+00:00","dateModified":"2024-03-13T12:44:50+00:00","mainEntityOfPage":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/"},"wordCount":260,"commentCount":0,"publisher":{"@id":"https:\/\/www.everpharma.com\/de\/#organization"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png","articleSection":["News"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/","url":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/","name":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung - EVER Pharma","isPartOf":{"@id":"https:\/\/www.everpharma.com\/de\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#primaryimage"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#primaryimage"},"thumbnailUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png","datePublished":"2020-10-21T08:21:00+00:00","dateModified":"2024-03-13T12:44:50+00:00","breadcrumb":{"@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#primaryimage","url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png","contentUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2021\/05\/Cabazitaxel_Combined-1-1024x355.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.everpharma.com\/de\/news\/ever-pharma-erhaelt-eu-zulassung-fuer-neue-innovative-cabazitaxel-formulierung\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.everpharma.com\/de\/"},{"@type":"ListItem","position":2,"name":"EVER Pharma erh\u00e4lt EU-Zulassung f\u00fcr neue innovative Cabazitaxel Formulierung"}]},{"@type":"WebSite","@id":"https:\/\/www.everpharma.com\/de\/#website","url":"https:\/\/www.everpharma.com\/de\/","name":"EVER Pharma","description":"Dedicated to health.","publisher":{"@id":"https:\/\/www.everpharma.com\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.everpharma.com\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":["Organization","MedicalOrganization"],"@id":"https:\/\/www.everpharma.com\/de\/#organization","name":"EVER Pharma","url":"https:\/\/www.everpharma.com\/de\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/logo\/image\/","url":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2022\/07\/ever-pharma-logo.png","contentUrl":"https:\/\/www.everpharma.com\/wp-content\/uploads\/2022\/07\/ever-pharma-logo.png","width":240,"height":67,"caption":"EVER Pharma"},"image":{"@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/logo\/image\/"},"legalName":"EVER Neuro Pharma GmbH","foundingDate":"1934-01-01","description":"EVER Pharma is a fully integrated specialty pharmaceuticals company specializing in the research, development, and production of sterile injectables and specialty generics for neurology, oncology, intensive care, and hormone therapeutics worldwide.","address":{"@type":"PostalAddress","streetAddress":"Oberburgau 3","addressLocality":"Unterach am Attersee","addressRegion":"Ober\u00f6sterreich","postalCode":"4866","addressCountry":"AT"},"contactPoint":{"@type":"ContactPoint","contactType":"customer service","telephone":"+43 7665 20555 0","email":"office@everpharma.com"},"sameAs":["https:\/\/www.linkedin.com\/company\/ever-pharma\/","https:\/\/www.wikidata.org\/wiki\/Q30268961"]},{"@type":"Person","@id":"https:\/\/www.everpharma.com\/de\/#\/schema\/person\/fddfefac0cbd5adf0a20c4e09a52cd65","name":"Magdalena","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e81cd7fba1e19c19fca1ea100bdf2dc3d182f19e790ce2afa3446fd8017b4fd0?s=96&d=mm&r=g","caption":"Magdalena"},"sameAs":["https:\/\/everpharma.com"],"url":"https:\/\/www.everpharma.com\/de\/author\/mschmitzberger\/"}]}},"acf":[],"_links":{"self":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/1520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/comments?post=1520"}],"version-history":[{"count":10,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/1520\/revisions"}],"predecessor-version":[{"id":4176,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/posts\/1520\/revisions\/4176"}],"wp:attachment":[{"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/media?parent=1520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/categories?post=1520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.everpharma.com\/de\/wp-json\/wp\/v2\/tags?post=1520"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}